Syndax is developing a pipeline of combination therapies in multiple cancer indications. Its lead product candidate, Entinostat, is currently being evaluated in a Phase III clinical trial for advanced HR+ breast cancer. Syndax advanced Entinostat to this pivotal trial based on positive Phase IIb results, meeting endpoints with statistical significance in both PFS and OS. The Phase III PFS readout is expected by YE 2017. Entinostat has been granted Breakthrough Therapy designation by the FDA for the treatment of advanced breast cancer. It is also being evaluated in Phase Ib/II trials with Merck for NSCLC and melanoma, with Genentech for TNBC and Pfizer and Merck KGaA for ovarian cancer.